Judeline Casimir: Preeclampsia Awareness Month – Moving From Knowing the Risks to Saving Lives
Judeline Casimir, CEO, Founder of Casimir Public Health Empowerment, shared a post on LinkedIn:
“May is Preeclampsia Awareness Month.
And this is one of the clearest examples of a larger issue in maternal health:
We know.
Preeclampsia affects 5–8% of pregnancies in the U.S.
- We know the symptoms.
- We know it can occur up to 6 weeks postpartum.
- We know Black women are at higher risk.
And yet outcomes are still inconsistent.
So the question is no longer:
- What do we need to know?
It’s:
Why isn’t what we already know working?
Because in many cases:
- Symptoms are dismissed
- Guidance is unclear
- Postpartum follow-up is inconsistent
And mothers are left navigating risk on their own.
This is the gap.
The space between clinical knowledge and real-world care delivery.
Awareness matters.
But outcomes change when systems are designed to respond in time.
If your organization is working to improve maternal outcomes, the next step is clear:
Identify where your system is failing to translate what it already knows.
Let’s fix that.”

Stay updated with Hemostasis Today.
-
Aug 31, 2026, 15:44Andrea Boccatonda: Special Issue on Pulmonary Embolism and Venous Thromboembolism
-
Aug 31, 2026, 15:41Adrien Jossart: Acute Thrombotic Storm Following Single Heparin Bolus
-
Aug 31, 2026, 15:36Bernhard Gerber: Myocardial Platelet Activation Linked to Microvascular Obstruction After STEMI
-
Aug 31, 2026, 15:34Higher Fibrinogen γ′ Linked to Increased Risk of Recurrent Arterial Thrombosis – Journal of Thrombosis and Haemostasis
-
Aug 31, 2026, 15:21Ney Carter Borges: Anticoagulation Versus Antiplatelet Therapy After TAVI ESC 26
-
Aug 31, 2026, 15:13Nahid A. Qushmaq: MicroRNAs as Prognostic Biomarkers in Septic Patients
-
Aug 31, 2026, 14:32Mahir Khalil Ibrahim Jallo: Hot Topic From The ESC 2026 Munich
-
Aug 31, 2026, 14:28Ruben Mesa: FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
-
Aug 31, 2026, 14:28Francisco Chacón-Lozsán: Should We Anticoagulate AF Patients With Only One Non-Sex Stroke Risk Factor?